Published in
Elsevier, The Lancet Oncology, 5(17), p. 651-662
DOI: 10.1016/s1470-2045(16)00078-4
Links
Tools
Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial
Journal article published in 2016 by
Timothy M. Nywening,
Andrea Wang-Gillam,
Dominic E. Sanford,
Brian A. Belt,
Roheena Z. Panni,
Brian M. Cusworth,
Rebecca K. Nieman,
Adetunji T. Toriola 
,
Lori A. Worley,
Motoyo Yano,
Kathryn J. Fowler,
A. Craig Lockhart,
Rama Suresh,
Benjamin R. Tan,
Kian-Huat Lim
and other authors.
,
Lori A. Worley,
Motoyo Yano,
Kathryn J. Fowler,
A. Craig Lockhart,
Rama Suresh,
Benjamin R. Tan,
Kian-Huat Lim
and other authors.
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 